• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Connecticut Innovations invests $1.5M in New Haven Pharmaceuticals

Connecticut Innovations invests $1.5M in New Haven Pharmaceuticals

October 31, 2012
CenterWatch Staff

Connecticut Innovations (CI), the state's quasi-public authority responsible for growing Connecticut businesses through innovative financing tools and assistance has made a $1.5 million investment in New Haven Pharmaceuticals (NHP), a specialty pharmaceuticals company of New Haven, Conn., through its Eli Whitney Fund.

CI's investment was part of a $6.6 million Series A funding round also involving EJ Funds, Kuzari Group, Advantage Capital Partners, Yale University and individual investors.

NHP is developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company's products employ proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience.

“We have a high degree of confidence in the company's seasoned team and its ability to execute on its plan to develop and commercialize a line of pharmaceuticals which includes a cardiovascular product near NDA submission," said Claire Leonardi, CEO and executive director of CI.

NHP president and CEO, Patrick Fourteau, said, "Based on my many years of experience successfully launching and commercializing new drugs, there is significant commercial opportunity not only for our lead product, but also for the other products NHP plans to develop. My plan is to build NHP into a successful specialty pharmaceuticals company which generates both a generous return for its investors and jobs for our home state."

NHP's most advanced product candidate, NHP-554C, is initially being developed as a prescription, anti-platelet therapy for the secondary prevention of stroke and acute cardiovascular events in patients who have had a previous such event. The company is also developing products based on Yale University technology that will lower stomach acid, alone, or in combination with other drugs. A target patient population for such products is persons suffering from gastro-esophageal reflux disease (or GERD).

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing